To deliver dermatology solutions and products offering the best quality, cost and service benefits the company’s manufacturing capacity is spread across the following sites. The French and Canadian plants have been extended in order to optimise and increase production capacity and ensure best-in-class standards for quality, safety and the environment. In 2013, the five sites will produce 135 million units.
Laboratoires Galderma SAS
Zone Industrielle - Touvière
74540 Alby sur Chéran - France
With a workforce of 200, the dermatology company’s French site has an annual production capacity of 30 million units. It manufactures the liquid and semi-liquid forms of products on five platforms and eight production lines and supplies over sixty countries in Europe, the Middle East, Africa, Australia, Asia and South America. The site has received ISO 14001 and OHSAS 18001 certifications and has been certified by several Health Agencies.
Galderma’s fifty-strong Industrial Development team is also based at the Alby-sur-Chéran site in the French Alps. The unit develops and improves manufacturing processes for new dermatology solutions and products, acquisitions and transfers, and supplies reference raw materials. It also produces clinical batches for trials worldwide. Industrial Development is tasked with leveraging dermatology company Galderma’s technical process.
Visiting address: Fyrisvallsgatan 7
75228 Uppsala - Sweden
Galderma's site in Uppsala, Sweden is the Global Aesthetic Center of Excellence with nearly 400 employees as well as world-class research and manufacturing. The site is responsible for Innovation, Development, Manufacturing and Strategic brand management for aesthetic and corrective treatments. A majority of the products in the aesthetic & corrective portfolio is based on the company’s patented technology, NASHA™, for the production of stabilized non-animal hyaluronic acid.
The manufacturing site employs 170 people and has served the market worldwide with leading brands like Restylane and Macrolane since 1996.
Galderma Production Canada Inc.
19400 Route Trans-Canada Hwy
Baie d'Urfé, Québec
H9X 3S4 - Canada
Employing 220 people, dermatology company Galderma’s Canadian site, near to Montreal, has seven manufacturing platforms and eight packaging lines offering a combined annual production capacity of 45 to 50 million units. Liquid and semi-liquid forms are manufactured here: pharmaceutical products for the US market and non-prescription products for all the markets worldwide. The plant is ISO 14001, OHSAS 18001 as well as FDA, ANVISA and Santé Canada certified.
Galderma Brasil Ltda.
Rodovia SP 101 - Campinas-Monte Mor, Km 9
Condominio Techtown - CEP 13186-904
Hortolândia-SP - Brazil
Galderma's Brazilian site came on stream in November 2004 and today employs about 35 people. Specializing in liquid and paste forms, it offers an annual production capacity of 5 million units. Products manufactured here are shipped throughout Brazil and other Latin American countries.
Spirig Pharma AG
4622 Egerkingen – Switzerland
The annual production of 20 Mio units, initially for 12 markets, will soon supply over 60 countries in Europe, the Middle East, Africa, Australia, Asia and South America. With a workforce of 160 employees the plant produces liquid, semi-solid and solid dosage forms.
Galderma’s Self-medication business and R&D unit are also situated in Egerkingen, as is Galderma’s Swiss affiliate.